The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Annual Report 2020 Download
Ian Crosbie

Chief Executive Officer

Company Overview

“Sequana Medical is at an exciting phase in its development with clear ambitions to accelerate its commercial growth and innovation. We continue to invest in our alfapump® and alfapump® DSR technologies to bring these innovative treatment options to a broader patient group and address important unmet medical needs, while creating value for shareholders.”

Share Price


ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33

EURO 22.40



For more information, please consult Euronext

Investor Tool Kit

2020 Annual Report

Download .pdf

Investor presentation

Download .pdf

Company Fact Sheet

Download .pdf

Financial Calendar

March 17, 2022

Full year results 2021


September 8, 2022

Half year results 2022

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.